Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:459-466

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Holvoet, P.
Right arrow Articles by Collen, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Holvoet, P.
Right arrow Articles by Collen, D.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Related Collections
Right arrow Animal models of human disease
Right arrow Genetically altered mice
Right arrow Gene therapy
Right arrow Lipid and lipoprotein metabolism
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2000;20:459.)
© 2000 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

The Arg123-Tyr166 Central Domain of Human ApoAI Is Critical for Lecithin:Cholesterol Acyltransferase–Induced Hyperalphalipoproteinemia and HDL Remodeling in Transgenic Mice

Paul Holvoet; Bart De Geest; Sophie Van Linthout; Marleen Lox; Sophie Danloy; Kathleen Raes; Désiré Collen

From the Center for Molecular and Vascular Biology, University of Leuven, Leuven, Belgium.

Correspondence to Paul Holvoet, Center for Molecular and Vascular Biology, University of Leuven, Campus Gasthuisberg, O & N, Herestraat 49, B-3000 Leuven, Belgium. E-mail paul.holvoet{at}med.kuleuven.ac.be

Abstract—High density lipoprotein (HDL) metabolism and lecithin:cholesterol acyltransferase (LCAT)–induced HDL remodeling were investigated in transgenic mice expressing human apolipoprotein (apo) AI or an apoAI/apoAII chimera in which the Arg123-Tyr166 domain of apoAI was substituted with the Ser12-Ala75 domain of apoAII. Expression of apoAI and of the apoAI/apoAII chimera resulted in a respective 3.5-fold and 2.9-fold increase of HDL cholesterol. Human LCAT gene transfer into apoAI-transgenic mice resulted in a 5.1-fold increase of endogenous LCAT activity. This increase was associated with a 2.4-fold increase of the cholesterol ester–to–free cholesterol ratio of HDL, a shift from HDL3 to HDL2, and a 2.4-fold increase of HDL cholesterol levels. Agarose gel electrophoresis revealed that human LCAT gene transfer into human apoAI–transgenic mice resulted in an increase of pre-ß-HDL and of pre-{alpha}-HDL. In contrast, human LCAT gene transfer did not affect cholesterol levels and HDL distribution profile in mice expressing the apoAI/apoAII chimera. Mouse LCAT did not "see" a difference between wild-type and mutant human apoAI, whereas human LCAT did, thus localizing the species-specific interaction in the central domain of apoAI. In conclusion, the Arg123-Tyr166 central domain of apoAI is not critical for in vivo lipoprotein association. It is, however, critical for LCAT-induced hyperalphalipoproteinemia and HDL remodeling independent of the lipid-binding properties of apoAI.


Key Words: transgenic mice • adenovirus • apoAI • LCAT • HDL remodeling




This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
C. Christoffersen, M. Jauhiainen, M. Moser, B. Porse, C. Ehnholm, M. Boesl, B. Dahlback, and L. B. Nielsen
Effect of Apolipoprotein M on High Density Lipoprotein Metabolism and Atherosclerosis in Low Density Lipoprotein Receptor Knock-out Mice
J. Biol. Chem., January 25, 2008; 283(4): 1839 - 1847.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
H.-h. Li, M. J. Thomas, W. Pan, E. Alexander, M. Samuel, and M. G. Sorci-Thomas
Preparation and incorporation of probe-labeled apoA-I for fluorescence resonance energy transfer studies of rHDL
J. Lipid Res., December 1, 2001; 42(12): 2084 - 2091.
[Abstract] [Full Text] [PDF]


Home page
Arterioscler. Thromb. Vasc. Bio.Home page
P. Holvoet, K. Peeters, S. Lund-Katz, A. Mertens, P. Verhamme, R. Quarck, D. Stengel, M. Lox, E. Deridder, H. Bernar, et al.
Arg123-Tyr166 Domain of Human ApoA-I Is Critical for HDL-Mediated Inhibition of Macrophage Homing and Early Atherosclerosis in Mice
Arterioscler. Thromb. Vasc. Biol., December 1, 2001; 21(12): 1977 - 1983.
[Abstract] [Full Text] [PDF]


Home page
J. Lipid Res.Home page
K.-H. Cho, D. M. Durbin, and A. Jonas
Role of individual amino acids of apolipoprotein A-I in the activation of lecithin:cholesterol acyltransferase and in HDL rearrangements
J. Lipid Res., March 1, 2001; 42(3): 379 - 389.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
D. C. McManus, B. R. Scott, V. Franklin, D. L. Sparks, and Y. L. Marcel
Proteolytic Degradation and Impaired Secretion of an Apolipoprotein A-I Mutant Associated with Dominantly Inherited Hypoalphalipoproteinemia
J. Biol. Chem., June 8, 2001; 276(24): 21292 - 21302.
[Abstract] [Full Text] [PDF]